Figure 2.

Kaplan‐Meier plot of percentage of dogs that have not yet met the composite cardiac endpoint as a function of time, in 366 dogs with congestive heart failure attributable to degenerative mitral valve disease and treated with either torasemide (n = 180) or furosemide (n = 186). The composite cardiac endpoint was a composite of spontaneous cardiac death, euthanasia for heart failure, and congestive heart failure class worsening. As compared to furosemide, torasemide was associated with a 2‐fold reduction in the risk of reaching the endpoint (adjusted HR = 0.47; 95% CI 0.27–0.82; P = 0.0077).